OasisLMS

Cervical cancer remains a major public health challenge globally, with a disproportionate burden in low- and middle-income countries (LMICs), despite the availability of effective prevention strategies and the global commitment to its elimination. Countries should screen 70% of women with a high-performance test twice in life to be on the pathway to elimination. 

Cervical screening not only involve collecting and testing a sample, for a program to be cost-effective, women who screen positive should complete the screening continuum (triage, treatment, follow-up). 

Current high-performance HPV tests offer the possibility of identifying individual or grouped carcinogenic HPV types. HPV limited or extended genotyping offers a built-in molecular triage that allows for simple stratification and prioritized management of HPV-positive women according to the risk for cervical pre-cancer and cancer granted by specific HPV types groups.  

In this webinar, recommendations primarily for the general population of women, with consideration of program capacity, particularly in relation to follow-up and treatment services, as well as preferred screening strategies under varying resource conditions that can be applied in different settings will be presented.  

Treatment introduction by Hennie Botha 

Presentation by Maribel Almonte 

Moderated by Mila Salcedo and Ida Pratt-Ismail